MAPT and Alzheimer disease: Among these tau-interacting mitochondrial proteins, Oxct1 has been identified as a p–tau interacting protein [151] and a therapeutic target of AD [152], SUCLG2 has been recognized as a determinator of CSF Aβ1-42 levels and [153] and promising for the AD signature protein [154].